8-K ·Filed Mar 24, 2026

NOTV

Inotiv, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001628280-26-020674
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Traders should monitor Inotiv's upcoming financial statements for signs of deteriorating liquidity, potential drawdowns on its credit facility, or further covenant risks. The stock may face downward pressure if liquidity concerns escalate.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
NOTV ▼ -94.55% at T+60d
SHORT call ✓ call won +94.55% · α vs SPY +108.87% · entry $0.3200 → $0.0174
Entry anchored
Mar 23, 03:58 PM ET
via exchange tick
T+1d
-6.25%
call +6.25% · α +6.82%
$0.3000
settled 6mo ago
T+5d
-15.63%
call +15.63% · α +15.20%
$0.2700
settled 6mo ago
T+20d
-6.25%
call +6.25% · α +15.15%
$0.3000
settled 5mo ago
T+60d
-94.55%
call +94.55% · α +108.87%
$0.0174
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Inotiv, Inc. announced that its lenders granted a waiver of the minimum liquidity covenant under its Credit Agreement for the March 20 and March 27, 2026 test dates. The waiver was limited to those specific dates and did not amend any other terms of the agreement.

Key Facts

  • Lenders waived the minimum liquidity covenant for March 20 and March 27, 2026 test dates under the Credit Agreement dated November 5, 2021.
  • The waiver was limited to the liquidity covenant for those specific dates and did not involve any amendments to the underlying Credit Agreement.
  • This indicates that Inotiv failed to meet its minimum liquidity requirements, triggering the need for a waiver.

Financial Impact

Significant liquidity pressure — company failed to meet covenant requirements, indicating potential cash flow or balance sheet stress.

liquiditydebt compliancefinancial flexibility

Risk Factors

  • Future inability to obtain covenant waivers if financial performance does not improve.
  • Potential restrictions on borrowing capacity or acceleration of debt if covenants are breached again.
  • Increased risk of credit downgrade or higher borrowing costs.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-020674
Document: 0001628280-26-020674-index-headers.html0001628280-26-020674
Document: 0001628280-26-020674-index.html0001628280-26-020674
Document: 0001628280-26-020674.txt0001628280-26-020674
4 reports for NOTV
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +96.13%Jun 1, 2026
Filters
Rows
Reports for NOTV — sortable, filterable
TypeNow
Jun 8, 2026
16w ago
8-K
BEARISH ★ 9/10
$0.0950 $0.0799▲ +15.89%▲ +14.32%—
Jun 3, 2026
17w ago
8-K
BEARISH ★ 8/10
$0.1200 $0.0900▲ +25.00%▲ +25.40%—
Jun 1, 2026
17w ago
8-K
BEARISH ★ 7/10
$0.3100 $0.2600▲ +16.13%▲ +16.27%—
Mar 24, 2026
27w ago
8-K
BEARISH ★ 7/10
$0.3200 $0.3000▲ +6.25%▲ +6.82%—
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (38h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access